Company intelligence / Profile preview

Atticus Medical

Ownership: Private
Employees: ~69
Development stage: Phase 2

Overview

Atticus Medical is a clinical-stage biotechnology company focused on developing innovative medicines for infectious diseases that disproportionately affect disadvantaged and marginalized populations. Their lead program, AM‑2, targets scabies and aims for regulatory approval. Additional programs target demodex blepharitis and head lice infestations. The company's mission centers on equitable healthcare access globally, with an emphasis on social impact.

Therapeutic areas: OphthalmologyInfectious Diseases
Modalities: Small molecules (inferred from infectious disease focus and mention of moxidectin)Other anti-parasitic agents (inferred)
Industry: Biotech

Drug pipeline

1 asset

moxidectin

Phase 2

Indications: Scabies, Demodex blepharitis, Head lice infestation

Beyond the preview

Go deeper on Atticus Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atticus Medical.

Explore the full profile